-
1 Comment
Eris Lifesciences Limited is currently in a long term uptrend where the price is trading 24.3% above its 200 day moving average.
From a valuation standpoint, the stock is 44.1% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 6.9.
Eris Lifesciences Limited's total revenue rose by 14.5% to $3B since the same quarter in the previous year.
Its net income has increased by 42.0% to $902M since the same quarter in the previous year.
Based on the above factors, Eris Lifesciences Limited gets an overall score of 3/5.
Sector | Healthcare |
---|---|
Industry | Drug Manufacturers - Specialty & Generic |
Exchange | NSE |
CurrencyCode | INR |
ISIN | INE406M01024 |
Dividend Yield | 1.0% |
---|---|
Beta | 0.12 |
Market Cap | 201B |
PE Ratio | 60.89 |
Target Price | 1512.5555 |
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India. The company offers various branded formulations in various therapeutic areas, such as anti"diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and ante-natal care solutions. It offers its products through wholesale drug distributors, and stockiest and retail pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is based in Ahmedabad, India.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ERIS.NSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025